Low Dose Naltrexone for Alcohol

Low-dose naltrexone, or LDN, is a 1 to 4.5 mg compounded dose of a standard alcohol drug, promoted online for drinking. Its alcohol evidence is close to zero, while standard 50 mg naltrexone is proven.

Jessica Miller is the Content Manager of Addiction HelpWritten by
Kent S. Hoffman, D.O. is a founder of Addiction HelpMedically reviewed by Kent S. Hoffman, D.O.
Last updated

Battling addiction & ready for help?

Find Treatment Now

What Low Dose Naltrexone Is

Low-dose naltrexone, usually shortened to LDN, is the same drug as the standard alcohol medication, given at a small fraction of the dose. It is typically compounded at 1 to 4.5 mg, against the 50 mg tablet the FDA approved for alcohol use disorder[1].

If you have read that LDN can quiet your drinking, that is a fair question with a straight answer. Standard-dose naltrexone has strong evidence for alcohol. LDN has almost none, and the two are not the same treatment wearing different labels.

Curious whether low-dose naltrexone could help your drinking? Talk to a clinician first, and get help now if you are in crisis. Call or text 988 any time.
If you or someone you love is in immediate danger or thinking about suicide, call or text 988 (Suicide and Crisis Lifeline), any time.

What to do:

  • Do not stop heavy daily drinking on your own. After long, heavy drinking, quitting abruptly can trigger seizures or delirium tremens, which can be fatal. A supervised alcohol detox makes stopping safe.
  • LDN is not the proven option, and it is not a detox medicine. The medication with real evidence for drinking is standard 50 mg naltrexone, laid out in medications for alcohol use disorder.
  • Talk to a clinician before starting anything for drinking. Using naltrexone at any dose is a medical decision, and there is a firm opioid-safety rule that comes first.

Find treatment today →

AddictionHelp.com Fast Facts
  • LDN is a very low dose of a standard alcohol drug. It is compounded at about 1 to 4.5 mg, far below the 50 mg naltrexone tablet the FDA approved for alcohol use disorder[1].
  • Its evidence for drinking is close to zero. A 2025 review of 68 low-dose naltrexone studies covered pain and autoimmune conditions and deliberately left out alcohol use disorder[2].
  • Standard 50 mg naltrexone is the proven option. Pooling 50 trials and nearly 7,800 people, it lowered the return to heavy drinking to about 83% of the placebo level[3].
  • LDN is thought to work through a different route. At a few milligrams it is proposed to nudge the immune and endorphin systems rather than block reward, a mechanism still not fully mapped[4].
  • One safety rule applies at any dose. Naltrexone can throw someone into sudden opioid withdrawal, so anyone using opioids must be off them first[1].

LDN and Standard Naltrexone Are Not the Same Treatment

The gap between the two doses is not a technicality — it changes the mechanism, the evidence, and the intended use. Standard naltrexone is a finished, approved alcohol medication. LDN is an investigational idea borrowed from pain and autoimmune care, where most of its research actually sits[2].

Interest is not evidencePlenty of people are talking about LDN for alcohol. That is interest, not proof. Until a real trial tests it, LDN for drinking is a reasonable question to raise with a clinician, not a treatment with results behind it.

Because standard tablets are made only at 50 mg, any lower dose has to be mixed by a compounding pharmacy[1]. That single fact shapes much of the LDN story, from cost to quality to the shortage of large trials.

Low-dose naltrexone (LDN) Standard-dose naltrexone
Typical dose About 1 to 4.5 mg, compounded 50 mg oral tablet, or the 380 mg monthly Vivitrol shot
FDA approval None; used off-label Approved for alcohol use disorder[1]
Evidence for drinking No controlled trials[2] 50 trials, nearly 7,800 people[3]
Proposed action Immune and endorphin modulation[4] Steady blockade of alcohol’s reward[3]
Where it is mainly studied Chronic pain and autoimmune conditions[2] Alcohol and opioid use disorder[1]

What the Evidence Actually Shows for LDN and Alcohol

The most important point comes first, stated plainly. No randomized controlled trials, controlled studies, or published case reports have tested low-dose naltrexone for drinking. The enthusiasm online has run well ahead of anything the research can support.

There Are No Controlled Trials of LDN for Alcohol Use Disorder

The clearest sign of the gap comes from the largest recent review. A 2025 scoping review examined 68 studies of low-dose naltrexone and set alcohol use disorder aside on purpose, because its inclusion rule was off-label use, meaning not for alcohol or opioids[2].

Randomized controlled trials are how a drug earns its place, and for LDN and drinking there are none to weigh. That absence is the finding. It is not evidence that LDN fails, but it is not permission to treat it as effective either.

The LDN Research That Exists Is About Pain, Not Drinking

Where LDN has been studied, the conditions are different. The developing evidence sits in fibromyalgia, chronic pain, multiple sclerosis, and complex regional pain syndrome, not alcohol[2][5]. A 2025 evaluation in veterans, for instance, tracked LDN for chronic pain and measured modest pain-score drops[6].

Those results, whatever their strength, do not carry over to drinking. Pain relief and reduced alcohol reward are different targets in different systems, and a benefit in one says nothing certain about the other. The pain findings are real; their relevance to alcohol is not established.

How LDN Is Proposed to Work Differently

The doses do not just differ in size — they are thought to act in different directions. That contrast is the heart of why standard naltrexone helps drinking and why LDN may not.

Two doses, two opposite ideasStandard naltrexone holds the reward door shut. LDN is proposed to briefly tap that door, then let the body push back with more of its own feel-good signals. For drinking, that second idea may work against you, not for you.

Standard Naltrexone Blocks the Reward, LDN Nudges the Immune System

At 50 mg, naltrexone keeps a steady grip on the brain’s opioid receptors, so alcohol’s feel-good surge is blunted and heavy drinking pulls at you less[3]. Blocking that reward is the whole mechanism, and it is well established.

LDN, at a few milligrams, is far too low to hold that blockade. Instead it is proposed to act on microglia, the immune cells of the nervous system, easing inflammation through a route separate from classical reward blockade[4]. That mechanism is still incompletely understood.

The Proposed LDN Mechanism May Point the Wrong Way for Drinking

There is a second idea about LDN worth understanding, because it cuts against the alcohol goal. A brief, low-dose block is thought to make the body respond by producing more of its own endorphins, the opposite of a steady block.

If that rebound is real, it would raise the very reward signaling that standard naltrexone works to lower[3]. In theory, that could push against the goal of making alcohol less rewarding. No study has tested whether it helps, harms, or does nothing for drinking[2].

How LDN Differs From Standard Naltrexone and the Sinclair Method

For someone who wants to drink less, the useful comparison is not LDN versus nothing — it is LDN versus the naltrexone approaches that already have evidence. There are two worth knowing.

Standard-Dose Naltrexone Is the Evidence-Backed Option for Drinking

The 50 mg dose has some of the deepest evidence in addiction medicine. Pooling 50 trials with nearly 7,800 people, standard naltrexone lowered the return to heavy drinking to about 83% of the placebo level, and modestly cut the number of drinking days[3].

Human laboratory studies show the same drug reliably reduces alcohol craving and the buzz that drives another drink[7]. For people who struggle to take a daily pill, the once-monthly injection keeps more of them in treatment than the tablet does[8].

Standard-dose naltrexone for drinking What the research shows
Return to heavy drinking Cut to about 83% of the placebo level across 50 trials and nearly 7,800 people[3]
Drinking days Modestly reduced versus placebo[3]
Craving and the alcohol buzz Reliably lowered in human laboratory studies[7]
Staying in treatment The monthly injection keeps more people on treatment than the daily pill[8]
Low-dose (LDN) equivalent None of these results come from LDN doses[2]

The Sinclair Method Uses Standard-Dose Naltrexone, Not LDN

Some of the curiosity about flexible dosing traces back to the Sinclair Method, which has people take naltrexone about an hour before drinking so the reward fades over time. Worth being clear about one thing: that method uses the standard 50 mg dose, not LDN[1].

So if the appeal of LDN is taking naltrexone in a flexible, drink-targeted way, the approach with actual evidence already exists at the standard dose. You do not need a compounded milligram dose to use naltrexone against drinking.

Why People Are Exploring LDN for Drinking

The interest is real, and the reasons behind it make sense even though the evidence does not back the choice yet. Naming them plainly helps you weigh your own situation.

Worth asking your clinician“I have read about low-dose naltrexone for drinking. Is standard naltrexone a better-proven fit for me?” Naming it directly gets past the biggest barrier, which is that these options never come up at all.

The Reasons Are Understandable Even Though the Evidence Is Thin

Several threads pull people toward LDN, and each is worth taking seriously:

  • Side-effect worries about standard naltrexone, such as nausea, tiredness, or low mood, and the hope that a smaller dose is gentler
  • Access through integrative or functional-medicine clinics that already prescribe LDN for pain or fatigue[2]
  • Online communities where personal stories about drinking less circulate widely
  • Interest in flexible dosing, often after hearing about naltrexone taken before drinking

These are legitimate concerns from people trying to solve a hard problem. The trouble is that a lower dose is a different mechanism, not simply a milder version of the proven one, so the trade may not buy what it seems to promise.

Testimonials Are Not the Same as Trial Evidence

Personal stories can be moving and still be an unreliable guide to whether a drug works. People change several things at once, expectations shape how they feel, and the wins get shared far more often than the letdowns. Controlled trials exist to cut through exactly that noise.

For a medication aimed at the reward system, that distinction matters even more, because belief and motivation can move drinking on their own for a while. A real effect has to outlast that, and for LDN and alcohol, no trial has looked.

The Safety Rules That Apply to Any Naltrexone Dose

Low dose does not mean low caution. Two safety points hold at every dose of naltrexone, and one of them is firm enough that skipping it can land someone in the hospital.

Naltrexone at Any Dose Can Trigger Opioid Withdrawal

The firm rule comes first. Because naltrexone blocks opioid receptors, taking it while opioids are in your body can set off sudden, severe precipitated withdrawal[1].

This applies at low doses too, so it is not something LDN sidesteps.

Before starting naltrexone at any dose, a clinician needs to know about:

  • Prescription opioid painkillers such as oxycodone, hydrocodone, or morphine
  • Methadone or buprenorphine, which need a longer, carefully managed washout
  • Any planned surgery where opioid pain control might be needed

Most guidance has people fully off short-acting opioids for about 7 to 10 days before any naltrexone dose, with a clinician confirming the timing[1].

LDN Side Effects and Compounding Quality Vary

At low doses, naltrexone is usually well tolerated, though not side-effect free. In a 2025 evaluation of veterans on LDN for pain, about 32% reported effects such as vivid dreams and drowsiness, most of them mild and early[6].

Because LDN is compounded rather than mass-produced, quality depends on the pharmacy. One study found compounded LDN capsules held their labeled strength within accepted limits for up to 360 days, which is reassuring where compounding is done well[9]. Some patients are titrated upward gradually to settle on a dose[10].

The Sensible Way to Think About LDN for Alcohol

Put the pieces together and the path becomes clear, and it is a hopeful one. There is a naltrexone approach for drinking that works — it is just the standard dose, not the low one.

Start with what is provenThe goal is to drink less or stop, and a proven tool for that already exists. Standard naltrexone is cheap, non-addictive, and backed by dozens of trials. LDN can wait for the evidence to catch up.

Standard Treatment First, Because It Is Proven and Underused

For almost anyone whose main problem is drinking, the highest-value step is the well-tested one. Standard naltrexone is inexpensive, non-addictive, and supported by 50 trials[3]. Yet it remains dramatically underused, so the common problem is not that it fails but that it is never offered.

That makes the practical priority straightforward. Before reaching for a compounded, unproven dose, the conversation worth having is whether the proven medication, on its own or through the Sinclair Method, fits you. It usually does.

What to Bring to Your Clinician

If you are weighing LDN for your drinking, a few clear points make the conversation productive:

  • Standard 50 mg naltrexone has strong evidence for alcohol; LDN has no controlled trials[3][2]
  • LDN’s proposed mechanism may work against reducing alcohol reward, not for it
  • Any naltrexone dose requires being off opioids first[1]
  • A private alcohol use self-assessment can show where your drinking stands before you choose a medication

The most useful conversation starts from what the evidence supports, and for drinking that points to the standard dose, backed by real trials and available today.

Getting Help for Alcohol Use Disorder

If you came here hoping a gentler dose could loosen alcohol’s grip, the good news is better than that. A proven, low-cost medication already can, and the support to start it is available right now.

Low-dose naltrexone may earn a role for drinking someday, if trials are done and the results hold[2]. Until then, the way out does not require waiting. Standard naltrexone, support, and a safe start are here today, and they work.

To go further on any piece of it:

Whenever you are ready, free and confidential help is one step away.

Get matched with treatment that fits your life →

Frequently asked questions

Does Low-Dose Naltrexone Work for Alcohol Use Disorder?

There is no good evidence that it does. No randomized controlled trials, controlled studies, or published case reports have tested low-dose naltrexone for drinking, and a 2025 review of 68 LDN studies deliberately left alcohol out because its research sits in pain and autoimmune conditions[2]. What does have strong evidence is standard 50 mg naltrexone, which lowered the return to heavy drinking to about 83% of the placebo level across 50 trials and nearly 7,800 people[3]. If your goal is to drink less, the standard dose is the option backed by research.

What Is the Difference Between LDN and Standard Naltrexone?

They are the same molecule at very different doses, and they are thought to work in different ways. Standard naltrexone is a 50 mg tablet approved for alcohol use disorder that steadily blocks the brain’s reward from alcohol[1][3]. Low-dose naltrexone is compounded at about 1 to 4.5 mg, far too low to hold that block, and is proposed instead to nudge the immune and endorphin systems through a route that is still not fully understood[4]. Because standard tablets are made only at 50 mg, LDN has to be mixed by a compounding pharmacy[1].

Is Low-Dose Naltrexone Safe to Take With Alcohol?

The main safety issue with any naltrexone dose is not alcohol but opioids. Because naltrexone blocks opioid receptors, taking it while opioids are in your body can cause sudden, severe precipitated withdrawal, so anyone on opioid painkillers, methadone, or buprenorphine must be off them first, usually for about 7 to 10 days[1]. At low doses naltrexone is generally well tolerated, though a 2025 evaluation found about 32% of users reported effects like vivid dreams and drowsiness[6]. Separately, if you drink heavily every day, do not stop suddenly on your own; a supervised detox is the safe way to quit.

How Is LDN Dosed and Where Do You Get It?

Low-dose naltrexone is typically compounded at about 1 to 4.5 mg, and some people are titrated upward gradually to find a dose they tolerate[10]. Because standard naltrexone is manufactured only as a 50 mg tablet, LDN is not available from an ordinary pharmacy and must be prepared by a compounding pharmacy with a prescription[1]. Quality depends on that pharmacy, though one study found compounded LDN capsules kept their labeled strength within accepted limits for up to 360 days[9]. For drinking specifically, remember that none of this dosing has been tested in alcohol trials[2].

Why Do People Try Low-Dose Naltrexone for Drinking?

Usually for understandable reasons. Some worry about side effects from standard naltrexone and hope a smaller dose is gentler; others come across LDN through integrative or functional-medicine clinics that prescribe it for pain or fatigue, or through online communities where personal stories circulate[2]. Interest in taking naltrexone flexibly, before drinking, also draws people toward the idea of a custom dose. These are real concerns, but a lower dose is a different mechanism, not a milder version of the proven one, and testimonials are not the same as trial evidence. The approach with actual evidence uses the standard dose.

Should I Try LDN or Standard Naltrexone First?

For almost anyone whose main problem is drinking, standard naltrexone is the sensible first choice. It is inexpensive, non-addictive, and backed by dozens of trials, and it can be started while you are still drinking or used before drinking through the Sinclair Method[3][1]. Low-dose naltrexone has no controlled trials for alcohol and a proposed mechanism that may work against reducing alcohol reward, so it is investigational at best for this use[2]. Bring both options to a clinician, who can also confirm the opioid-safety timing, and check your own pattern first with a private alcohol self-assessment.

Get Treatment Help

If you or someone you love is struggling with addiction, getting help is just a phone call away, or consider trying therapy online with BetterHelp.

Exclusive offer: 20% Off BetterHelp*

Following links to the BetterHelp website may earn us a commission that helps us manage and maintain AddictionHelp.com. *Get 20% off your first month of BetterHelp. Offer valid for new BetterHelp users only. Offer cannot be combined with insurance.

10 Sources
  1. McPheeters, Melissa, O'Connor, Elizabeth A, Riley, Sean, Kennedy, Sara M, et al. (2023). Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. https://doi.org/10.1001/jama.2023.19761
  2. Bahji, Anees, Bach, Paxton, Danilewitz, Marlon, Crockford, David, et al. (2022). Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis. J Addict Med. https://doi.org/10.1097/ADM.0000000000000992
  3. Leiber, Kayla K, Parker, Robert W (2025). Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review. Cureus. https://doi.org/10.7759/cureus.81086
  4. Patten, Denise K, Schultz, Bob G, Berlau, Daniel J (2018). The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders. Pharmacotherapy. https://doi.org/10.1002/phar.2086
  5. Younger, Jarred, Noor, Noorulain, McCue, Rebecca, Mackey, Sean (2013). Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. https://doi.org/10.1002/art.37734
  6. Due Bruun, Karin, Christensen, Robin, Amris, Kirstine, Vaegter, Henrik Bjarke, et al. (2024). Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(23)00278-3
  7. Parker, Claire E, Nguyen, Tran M, Segal, Dan, MacDonald, John K, Chande, Nilesh (2018). Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010410.pub3
  8. Cree, Bruce A C, Kornyeyeva, Elena, Goodin, Douglas S (2010). Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. https://doi.org/10.1002/ana.22006
  9. Sharafaddinzadeh, Naser, Moghtaderi, Ali, Kashipazha, Davood, Majdinasab, Nastaran, Shalbafan, Bita (2010). The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. https://doi.org/10.1177/1352458510366857
  10. Kunzler, Nathan M, Wightman, Rachel S, Nelson, Lewis S (2020). Opioid Withdrawal Precipitated by Long-Acting Antagonists. J Emerg Med. https://doi.org/10.1016/j.jemermed.2019.12.015
Written by
Jessica Miller is the Content Manager of Addiction Help

Editorial Director

Jessica Miller is the Editorial Director of Addiction Help. Jessica graduated from the University of South Florida (USF) with an English degree and combines her writing expertise and passion for helping others to deliver reliable information to those impacted by addiction. Informed by her personal journey to recovery and support of loved ones in sobriety, Jessica's empathetic and authentic approach resonates deeply with the Addiction Help community.

Reviewed by
  • Fact-Checked
  • Editor
Kent S. Hoffman, D.O. is a founder of Addiction Help

Co-Founder & Chief Medical Officer

Kent S. Hoffman, D.O. has been an expert in addiction medicine for more than 15 years. In addition to managing a successful family medical practice, Dr. Hoffman is board certified in addiction medicine by the American Osteopathic Academy of Addiction Medicine (AOAAM). Dr. Hoffman has successfully treated hundreds of patients battling addiction. Dr. Hoffman is the Co-Founder and Chief Medical Officer of AddictionHelp.com and ensures the website’s medical content and messaging quality.

Real Help. Real Recovery.

Compare centers, explore options and start your path to recovery today.

Find Treatment Now

"AddictionHelp.com is helping to make recovery available to EVERYONE!"

- Angela N.